查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197330

静脉治疗和静脉通路市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Intravenous (IV) Therapy and Vein Access Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计在预测期内（2022 年至 2027 年），静脉疗法 (IV) 和静脉通路市场将以 5% 的复合年增长率增长。

COVID-19 大流行对静脉治疗 (IV) 和静脉通路市场产生了重大影响。 例如，根据 2021 年 11 月发表的题为“针对 □□COVID-19 ARDS 的静脉免疫球蛋白治疗”的论文，静脉注射免疫球蛋白 (IVIG) 被推荐用于中度至重度 COVID-19 相关急性呼吸窘迫综合征 (ARDS)，并且与血栓栓塞不良事件增加有关。 此类研究可能在短期内对市场增长产生负面影响。 然而，由于输液疗法的研究和开发增加以及对家庭药物的需求增加，预计该市场在大流行后阶段将出现积极增长。 例如，根据过敏和哮喘网络 2022 年 3 月的更新，单克隆抗体通过静脉内 (IV) 或单剂量注射给药给诊断为 COVID-19 的人，并且这种疗法对 COVID-19 有效。据信使用抗体可以帮助人体抵抗感染。 此外，根据2020年10月发表的论文《The Use of Intravenous Immunoglobulin Gamma for the Treatment of Severe Coronavirus Disease 2019: A Randomized Placebo-Controlled Double-Blind Clinical Trial》，其对COVID-19重症感染患者有效免疫球蛋白给药有望改善临床结果，并有助于显着降低 SARS-CoV2 病毒感染的死亡率。 此类研究增加了对静脉治疗的需求，预计将在未来几年推动静脉治疗 (IV) 和静脉通路市场。

此外，慢性病的增加、全球手术数量的增加、静脉药物批准数量的增加以及静脉治疗和准入方面的技术进步不断增加等因素也在推动市场增长。

全球范围内慢性病发病率的上升和手术数量的增加推动了对静脉治疗和静脉通路装置的需求。 静脉内治疗用于输送各种慢性疾病药物，如类风湿性关节炎、克罗恩病、骨质疏鬆症、系统性狼疮、多发性硬化症、牛皮癣和痛风。 根据 Atlas of MS 2020 年 9 月的一份报告，全球有 280 万人患有多发性硬化症。 静脉内治疗也已成为外科手术的重要组成部分。 因此，增加外科手术将有助于市场增长。 例如，在一项名为“脊柱手术后静脉注射利多卡因预防谵妄和减轻疼痛的临床试验 (LIMPP)”的正在进行的临床试验研究中，为了尽量减少患者群体中的谵妄和阿片类药物的使用，研究了重建术后连续静脉注射利多卡因脊柱手术。 该考试由加州大学主办，预计将于 2024 年 9 月完成。 因此，此类研究将大大增加对静脉注射治疗的需求，并在未来几年增加对静脉注射和静脉通路装置的需求。

此外，根据 2021 年 6 月发表的一项题为“2020 年德国心臟手术报告”的研究报告。 根据德国胸心血管外科学会年度更新登记表，共有 92,809 例手术被归类为经典意义上的心臟手术，其中 29,444 例为单冠状动脉旁路移植术，35,469 例为单冠状动脉旁路移植术。瓣膜手术和单心移植手术增加了 2%，达到 340 例。 鑑于静脉治疗在心臟直视手术出血管理中的关键作用，其需求预计将影响未来几年 IV 和 IV 通路市场的增长。

此外，2021 年 9 月，B. Brown Medical 将推出带有可选气塞的新型 CARESAFE IV 给药装置。 CARESAFE IV Sets 是美国市场上第一个不含聚氯乙烯 (PVC) 和邻苯二甲酸二乙基己酯 (DEHP) 的强大的 IV 给药装置组合。

然而，与静脉治疗相关的并发症和经验丰富的医疗保健专业人员的短缺阻碍了市场的增长。

静脉治疗和准入市场趋势

静脉治疗和准入市场，植入式端口将占据主要市场份额

按类型来看，植入式端口细分市场预计将占据较大份额。 植入式端口是皮下或静脉内插入的装置。 它通常插入胸部右上侧锁骨下方约 1 英寸处，用于抽血或给药。

推动该细分市场增长的主要因素是技术进步和植入式端口的采用率不断提高。 例如，2020 年 7 月，Angiodynamics 的 SmartPort+Implantable Port 获得了美国食品药品监督管理局 (FDA) 的 510(k) 许可和欧盟委员会的 CE 标誌。

此外，由于对植入式端口的认识提高，植入式端口的使用也在增加。 例如，2021 年 2 月，BD-India 在 2 月 4 日世界癌症日推出了一项名为“PortShala”的化学端口特殊教育计划。 这些端口用于为癌症患者提供化学疗法。 这项工作的重点是提高所有癌症利益相关者和护理人员之间有关化学端口植入、管理和维护的信息水平。

因此，由于上述因素，预计该行业在预测期内将出现显着增长。

北美将占据很大的市场份额，预计在预测期内也会如此

在北美，预计美国将占据主要市场份额。 推动该国市场增长的主要因素是慢性病患病率增加和手术数量增加、医疗基础设施改善和技术进步不断增加。

例如，根据美国疾病控制和预防中心的数据，到 2020 年，美国将有大约 600,000 名妇女接受了子宫切除术。 根据全国妇女与家庭伙伴关係 2022 年 5 月的更新，美国的剖腹产率很高，现在大约有三分之一的新生儿是剖腹产。 所有这些程序都需要静脉注射药物和液体，从而推动了该国市场的增长。

一些市场参与者正在努力实施战略计划，从而为市场的增长做出贡献。 例如，2022 年 3 月，多元化商业阶段医疗技术公司 PAVmed Inc. 宣布，哥伦比亚巴兰基亚 Clinica Porto Azul 的医生将接受 IRB 批准的最多 40 名患者的首次试验。在人体（FIH）临床试验中，公司将PortIO肌内註射系统植入三人体内，报告该装置首次成功人体植入。 预计此类案例将大大有助于提高患者对 IV 治疗和 IV 接入装置的认识，从而增加该地区对 IV 治疗和 IV 接入装置的需求。

因此，由于上述因素，预计市场在预测期内将出现显着增长。

静脉疗法和静脉通路市场竞争对手分析

静脉治疗和通路市场是一个竞争激烈的市场，拥有全球和国际参与者。 主要参与者正在采用各种增长战略，例如合作伙伴关係、协议、联盟、新产品发布、地域扩张、兼併和收购，以增加他们的市场占有率。 市场上的主要参与者包括 Becton、Dickinson and Company、Terumo Medical Corporation、Vygon SAS、Teleflex Incorporated、Fresenius Kabi 等。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 全球范围内慢性病的增加和手术数量的增加
    • 输液治疗设备技术进步增加
  • 市场製约因素
    • 与输液治疗相关的并发症
    • 缺乏经验丰富的医疗保健专业人员
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按类型
    • 输液泵
    • 点滴套装
    • 嵌入式端口
    • 中心静脉导管
    • 其他产品
  • 通过申请
    • 扩容器
    • 药物管理
    • 血液製品
    • 其他应用程序类型
  • 按销售渠道
    • 医院药房
    • 零售药房
    • 其他分销渠道
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Polymedicure
    • Becton, Dickinson and Company
    • Tekni-Plex
    • Terumo Medical Corporation
    • Vygon SAS
    • Teleflex Incorporated
    • Fresenius Kabi
    • Smiths Medical, Inc.
    • Medtronic plc
    • Iradimed Corporation
    • ICU Medical, Inc
    • Baxter International
    • B. Braun Melsungen AG
    • AngioDynamics
    • Cardinal Health

第7章 市场机会与今后动向

简介目录
Product Code: 90580

The intravenous therapy (IV) and vein access market is expected to register a CAGR of 5% over the forecast period (2022-2027).

The COVID-19 pandemic has significantly impacted the intravenous therapy (IV) and vein access market. For instance, as per a November 2021 published article titled "Intravenous Immunoglobulin Therapy for COVID-19 ARDS", intravenous immunoglobulin (IVIG) did not significantly improve outcomes in moderate-to-severe COVID-19 associated acute respiratory distress syndrome (ARDS) and was associated with an increase in thromboembolic adverse events. Such studies are likely to have a short-term adverse impact on the market's growth. However, due to ongoing research and development activities in IV therapies and the rising demand for medication administration at home, the market is expected to grow positively in the post-pandemic phase. For instance, as per a March 2022 update by the Allergy & Asthma Network, monoclonal antibodies are given by intravenous (IV) or a single-dose injection to people diagnosed with COVID-19, and the therapy uses COVID-19 antibodies to help a person's body fight off the infection. In addition, as per an October 2020 published article titled "The Use of Intravenous Immunoglobulin Gamma for the Treatment of Severe Coronavirus Disease 2019: A Randomized Placebo-Controlled Double-Blind Clinical Trial," the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to improve the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Thus, such studies are anticipated to boost the demand for intravenous therapy, ultimately augmenting the intravenous therapy (IV) and vein access market over the coming years.

Furthermore, the market's growth can be attributed to factors such as the increasing incidences of chronic diseases, the growing number of surgeries worldwide, rising number of intravenous (IV) drug approvals, and increasing technological advancements in intravenous therapy (IV) and vein access.

The increasing number of incidences of chronic diseases and the growing number of surgeries worldwide is driving the demand for intravenous therapy and vein access devices. Intravenous therapy is used to deliver various medications for chronic conditions such as rheumatoid arthritis, Crohn's disease, osteoporosis, systemic lupus, multiple sclerosis, psoriasis, and gout. As per the September 2020 report by the Atlas of MS, 2.8 million people are living with Multiple Sclerosis around the globe. In addition, intravenous therapy is a key component of surgical procedures. Thus, the increasing number of surgical procedures contributes to market growth. For instance, an ongoing clinical trial study titled "A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain (LIMPP)" investigates continuous post-operative intravenous lidocaine infusion post-reconstructive spine surgery for minimizing delirium and opiate usage among the patient population. The University of California sponsored the trial, and it is expected to be completed by September 2024. Thus, such studies will greatly bolster the demand for IV therapy over the coming years, boosting the demand for IV and vein access devices.

Moreover, as per the research study published in June 2021, titled "German Heart Surgery Report 2020: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery", a total of 92,809 operations were classified as heart surgery procedures in the classical sense, of which 29,444 were isolated coronary artery bypass grafting procedures, 35,469 were isolated heart valve procedures, and the number of isolated heart transplantations increased by 2% to 340. Since IV therapies play a vital role in managing blood loss caused due to open-heart surgeries, the demand for such treatments is likely to impact the growth of the IV and vein access market over the coming years.

Moreover, in September 2021, B. Braun Medical Inc. launched its new CARESAFE IV Administration Sets with Optional AirStop. CARESAFE IV Sets are the first robust portfolio of IV administration sets in the United States market that are not made with polyvinyl chloride (PVC) and diethylhexyl phthalate (DEHP).

However, complications associated with intravenous therapy and a lack of experienced healthcare professionals hinder the market's growth.

Intravenous Therapy & Vein Access Market Trends

Implantable Ports Segment is Expected to Hold a Major Market Share in the Intravenous (IV) Therapy and Vein Access Market

By type, the implantable ports segment is expected to hold a major share in the market. Implantable ports are devices that are inserted under the skin and into a vein. They usually go in about an inch below the collarbone in the upper right chest for the withdrawal of blood or administration of drugs.

The major factors fuelling the segment's growth are the increasing number of technological advancements and the increasing adoption of implantable ports. For instance, in July 2020, AngioDynamics, Inc. received 510 (k) clearance from the United States Food & Drug Administration (FDA), as well as a CE Mark from the European Commission, for their SmartPort+ Implantable Port.

In addition, the use of implantable ports is increasing owing to the rising awareness of these devices among the patient population. For instance, in February 2021, BD-India launched a special educational program on chemo ports called PortShala on World Cancer Day, February 4th. These ports are used to deliver chemotherapy to cancer patients. The initiative focuses on upgrading information levels on implanting, administration, and maintenance of chemo ports among all cancer stakeholders and caregivers.

Thus, owing to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The United States is expected to hold a major share of the market in North America. The major factors fuelling the market growth in the country are the increasing prevalence of chronic diseases and the growing number of surgeries, improved healthcare infrastructure, and the rising number of technological advancements.

For instance, according to the Center for Disease Control and Prevention, in 2020, about 600,000 women in the United States had a hysterectomy. As per the National Partnership for Women & Families updates from May 2022, the C-section rate in the United States is high: about 1 in 3 women now gives birth by C-section. All these procedures require intravenous therapy for the administration of medications and fluids, which thus propels the market growth in the country.

Several market players are engaged in implementing strategic initiatives, thereby contributing to the market's growth. For instance, in March 2022, PAVmed Inc., a diversified commercial-stage medical technology company, reported that physicians at the Clinica Porto Azul in Barranquilla, Colombia, successfully implanted the company's PortIO Intraosseous Infusion System in three patients, the first human implants of the device, as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients. Such instances will significantly contribute toward increasing patient awareness regarding IV therapies and systems, augmenting the demand for intravenous therapy (IV) and vein access devices within the region.

Thus, the market is expected to witness significant growth during the forecast period due to the abovementioned factors.

Intravenous Therapy & Vein Access Market Competitor Analysis

The intravenous (IV) therapy and vein access market is competitive with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Becton, Dickinson and Company, Terumo Medical Corporation, Vygon SAS, Teleflex Incorporated, and Fresenius Kabi, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidences of Chronic Diseases and Growing Number of Surgeries Worldwide
    • 4.2.2 Increasing Technological Advancements in IV Therapy Devices
  • 4.3 Market Restraints
    • 4.3.1 Complications Associated with Intravenous Therapy
    • 4.3.2 Lack of Experienced Healthcare Professionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Infusion Pumps
    • 5.1.2 Intravenous Sets
    • 5.1.3 Implantable Ports
    • 5.1.4 Central Venous Catheters
    • 5.1.5 Other Products
  • 5.2 By Application
    • 5.2.1 Volume Expander
    • 5.2.2 Medication Administration
    • 5.2.3 Blood-based Products
    • 5.2.4 Other Application Types
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Other Distribution Channel
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Polymedicure
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Tekni-Plex
    • 6.1.4 Terumo Medical Corporation
    • 6.1.5 Vygon SAS
    • 6.1.6 Teleflex Incorporated
    • 6.1.7 Fresenius Kabi
    • 6.1.8 Smiths Medical, Inc.
    • 6.1.9 Medtronic plc
    • 6.1.10 Iradimed Corporation
    • 6.1.11 ICU Medical, Inc
    • 6.1.12 Baxter International
    • 6.1.13 B. Braun Melsungen AG
    • 6.1.14 AngioDynamics
    • 6.1.15 Cardinal Health

7 MARKET OPPORTUNITIES AND FUTURE TRENDS